Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency

Piotr Ponikowski, Dirk J. van Veldhuisen, Josep Comin-Colet, Georg Ertl, Michel Komajda, Viacheslav Mareev, Theresa A. McDonagh, Alexander Parkhomenko, Luigi Tavazzi, Victoria Levesque, Claudio Mori, Bernard Roubert, Gerasimos Filippatos, Frank Ruschitzka, Stefan D. Anker

    Research output: Contribution to journalArticleResearchpeer-review

    27 Citations (Scopus)

    Abstract

    © 2014 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology. Background: Iron deficiency (ID) is a common co-morbidity associated with chronic heart failure (CHF), which has unfavourable clinical and prognostic consequences. In Ferinject Assessment in Patients with IRon Deficiency and Chronic Heart Failure (FAIR-HF), the treatment with i.v. ferric carboxymaltose (FCM) improved symptoms and quality of life over a 24 week period. Ferric CarboxymaltOse evaluatioN on perFormance in patients with IRon deficiency in coMbination with chronic Heart Failure (CONFIRM-HF) was designed to test a simplifieddosage scheme of FCM during a longer follow-up period. Methods: CONFIRM-HF, a double-blind, multi-centre, prospective, randomized, two-arm study, enrolled ambulatory patients with symptomatic CHF [New York Heart Association (NYHA) class II/III] with left ventricular ejection fraction ≤45%, BNP >100 pg/mL, or NT-proBNP >400 pg/mL, presence of ID [defined as ferritin <100 ng/mL, or ferritin 100–300 ng/mL if transferrin saturation (TSAT) <20%], and haemoglobin (Hb) <15 g/dL. Patients were randomized 1:1 to treatment with FCM or placebo for 52 weeks. Primary endpoint is change in 6-minute walk test (6MWT) distance from baseline to Week 24. Secondary endpoints are: change in 6MWT from baseline to Weeks 6, 12, 36, and 52; Patient Global Assessment score at Weeks 6, 12, 24, 36, and 52; and change from baseline to Weeks 6, 12, 24, 36, and 52 in NYHA class, fatigue score, and quality of life. Safety endpoints include overall safety over the treatment period of 52 weeks. Study medication was administered in single doses as undiluted bolus injection of up to 1000 mg of iron or normal saline at Day 0 and Week 6 up to iron repletion. Further doses of study medication could be administered at Weeks 12, 24, and 36 if a patient still had ID. Results: Overall, 304 patients were recruited in 41 centres in nine countries. Conclusion: This study will provide further information on the efficacy and safety of iron therapy with i.v. FCM in CHF patients with ID over a 1 year period using a simplified dosing scheme.
    Original languageEnglish
    Pages (from-to)52-58
    JournalESC heart failure
    Volume1
    Issue number1
    DOIs
    Publication statusPublished - 1 Jan 2014

    Keywords

    • Chronic heart failure
    • Ferric carboxymaltose
    • Functional capacity
    • Iron deficiency
    • Treatment

    Fingerprint Dive into the research topics of 'Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency'. Together they form a unique fingerprint.

  • Cite this

    Ponikowski, P., van Veldhuisen, D. J., Comin-Colet, J., Ertl, G., Komajda, M., Mareev, V., McDonagh, T. A., Parkhomenko, A., Tavazzi, L., Levesque, V., Mori, C., Roubert, B., Filippatos, G., Ruschitzka, F., & Anker, S. D. (2014). Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. ESC heart failure, 1(1), 52-58. https://doi.org/10.1002/ehf2.12006